Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER Specialty Care sales grew 18.3%, driven by strong Dupixent performance (+54.2% to €982 million). Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. General Medicines declined 7.5%, reflecting lower U.S. Diabetes sales, COVID environment and portfolio streamlining. CHC down 3.0% due to decreased sales of Cough & Cold related portfolio in Europe partially offset by Digestive Health brands. Leveraged business EPS as the result of prioritization within R&D and...
Source: finanznachrichten.de